



**BIOVERATIV AND BICYCLE THERAPEUTICS ENTER INTO STRATEGIC RESEARCH
COLLABORATION TO DEVELOP THERAPIES FOR HAEMOPHILIA AND SICKLE CELL DISEASE**

Bicycle to receive an upfront payment of \$10 million, with potential for future milestones

WALTHAM, Mass. and CAMBRIDGE, U.K., September 6, 2017 – Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialisation of innovative therapies for haemophilia and other rare blood disorders, and Bicycle Therapeutics Ltd., a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*[®]) product platform, today announced a research collaboration focused on the discovery, development and commercialisation of innovative therapies for haemophilia and sickle cell disease.

The collaboration will seek to identify and develop *Bicycles* to treat rare blood disorders. *Bicycles* are a new therapeutic modality that combine attributes of antibodies, small molecules and peptides within one molecule, enabling high selectivity and affinity while simultaneously being able to penetrate and bind to the target(s) of interest within the body.

Bicycle Therapeutics will be responsible for leading initial discovery activities through lead optimisation to candidate selection for two programs. Bioverativ will lead preclinical and clinical development, as well as subsequent marketing and commercialisation. Bioverativ will reimburse Bicycle for internal and external program-related costs.

Upon execution of the agreement, Bicycle will receive a \$10 million upfront payment and near-term research and development funding of \$4.2 million. Bicycle is eligible to receive up to \$410 million related to development, regulatory and commercialisation milestones for products planned under the two programs, as well as tiered single to low double-digit royalties related to product sales. Additional terms of the transaction are not being disclosed.

“We are constantly exploring new ways to do innovative science to find new molecules that can advance the care of people living with rare blood disorders,” said Tim Harris, Ph.D., D.Sc., Executive Vice President of Research and Development at Bioverativ. “This collaboration offers a unique opportunity to identify an entirely new therapeutic modality that may lead to meaningful new treatments and outcomes for people living with haemophilia and sickle cell disease. We are delighted to be working with Bicycle to pursue our shared goal of creating progress for patients with great unmet treatment needs.”

“We believe our *Bicycle* platform has extremely broad therapeutic potential and we are excited to work with Bioverativ, a standout leader in the haematology field, to explore *Bicycles* in this important area of clinical need,” said Kevin Lee, Chief Executive Officer of Bicycle Therapeutics. “Combining Bioverativ’s deep expertise in haematology with our powerful platform offers great promise for the development of novel, targeted therapies for patients. This alliance provides the latest validation of our *Bicycle* platform and furthers our strategy to evaluate its potential in a wide range of new disease areas.”

About Bioverativ

Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit bioverativ.com or follow [@bioverativ](https://twitter.com/bioverativ) on Twitter.

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other important diseases based on its proprietary bicyclic peptide (*Bicycle*[®]) product platform. *Bicycles* exhibit the affinity and exquisite target specificity usually associated with antibodies. Their small size enables rapid and deep tissue penetration, allowing tissues and tumours to be targeted from within. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, thus avoiding the liver and gastrointestinal tract toxicity often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead programs using *Bicycle Drug Conjugates*[®] to selectively deliver toxins to tumours. Bicycle Therapeutics enters into collaborations in order to advance its programs and realise the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com.

Bioverativ Safe Harbor

This press release contains forward-looking statements, including statements about the potential benefits and developments that may be achieved through the collaboration with Bicycle. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Bioverativ’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include, among others: uncertainty regarding the ability to achieve the expected benefits from the collaboration, including as a result of risks and uncertainties associated with drug development and commercialization; reliance on third parties over which Bioverativ may not always have full control; risks associated with collaborations; and other risks and uncertainties that are described in the Risk Factors section of Bioverativ’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and Bioverativ assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Bioverativ

Media Contact:

Marianne McMorrow

+1 781-663-4376

media@bioverativ.com

or

Investor Relations Contact:

Susan Altschuller

+1 781-663-4360

IR@bioverativ.com

Bicycle Therapeutics

Ten Bridge Communications (U.S.)

Sarah Sutton

Sarah@tenbridgecommunications.com

+1-518-932-3680

Consilium Strategic Communications (EU)

Mary-Jane Elliott / Chris Gardner / Ivar Milligan

Bicycle@consilium-comms.com

+44 20 3709 5700